Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Cisplatin in Advanced TNBC
NCT03644589Phase 2Withdrawn
- Sponsor
- University of Washington
- Start
- Apr 2019
- Primary completion
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by University of Washington. Primary endpoint: Efficacy of combination pembrolizumab and cisplatin up to 10 years. Planned start Apr 2019; status: withdrawn.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03644589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03644589.